Anticoagulant therapy in critical organ ischaemia/reperfusion injury

STBG Loubele, H ten Cate… - Thrombosis and …, 2010 - thieme-connect.com
STBG Loubele, H ten Cate, HMH Spronk
Thrombosis and haemostasis, 2010thieme-connect.com
Ischaemia/reperfusion (I/R) injury is central to a number of pathologies including myocardial
infarction and stroke. Several cellular processes are involved in the progress of I/R injury,
involving complex interactions between coagulation and inflammatory or apoptotic
processes. Besides for their anti-coagulant function, anticoagulant proteins such as
activated protein C (APC), active site inhibited factor VIIa (ASIS), tissue factor pathway
inhibitor (TFPI), and antithrombin (AT) are also known for their anti-inflammatory or cell …
Ischaemia/reperfusion (I/R) injury is central to a number of pathologies including myocardial infarction and stroke. Several cellular processes are involved in the progress of I/R injury, involving complex interactions between coagulation and inflammatory or apoptotic processes. Besides for their anti-coagulant function, anticoagulant proteins such as activated protein C (APC), active site inhibited factor VIIa (ASIS), tissue factor pathway inhibitor (TFPI), and antithrombin (AT) are also known for their anti-inflammatory or cell protective effects. This review gives an overview of the application of these anti-coagulants in several animal models of I/R injury in critical organs and describes the effects of these proteins on cellular processes including inflammation and apoptosis. The future testing of mutant forms of some of these inhibitors including APC in a clinical setting should be actively explored.
Thieme Connect